Correlation Between Foghorn Therapeutics and Immunovant

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Foghorn Therapeutics and Immunovant at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Foghorn Therapeutics and Immunovant into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Foghorn Therapeutics and Immunovant, you can compare the effects of market volatilities on Foghorn Therapeutics and Immunovant and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Foghorn Therapeutics with a short position of Immunovant. Check out your portfolio center. Please also check ongoing floating volatility patterns of Foghorn Therapeutics and Immunovant.

Diversification Opportunities for Foghorn Therapeutics and Immunovant

-0.04
  Correlation Coefficient

Good diversification

The 3 months correlation between Foghorn and Immunovant is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Foghorn Therapeutics and Immunovant in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunovant and Foghorn Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Foghorn Therapeutics are associated (or correlated) with Immunovant. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunovant has no effect on the direction of Foghorn Therapeutics i.e., Foghorn Therapeutics and Immunovant go up and down completely randomly.

Pair Corralation between Foghorn Therapeutics and Immunovant

Given the investment horizon of 90 days Foghorn Therapeutics is expected to generate 1.43 times more return on investment than Immunovant. However, Foghorn Therapeutics is 1.43 times more volatile than Immunovant. It trades about -0.06 of its potential returns per unit of risk. Immunovant is currently generating about -0.14 per unit of risk. If you would invest  811.00  in Foghorn Therapeutics on August 28, 2024 and sell it today you would lose (59.00) from holding Foghorn Therapeutics or give up 7.27% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Foghorn Therapeutics  vs.  Immunovant

 Performance 
       Timeline  
Foghorn Therapeutics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Foghorn Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Foghorn Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024.
Immunovant 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Foghorn Therapeutics and Immunovant Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Foghorn Therapeutics and Immunovant

The main advantage of trading using opposite Foghorn Therapeutics and Immunovant positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Foghorn Therapeutics position performs unexpectedly, Immunovant can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunovant will offset losses from the drop in Immunovant's long position.
The idea behind Foghorn Therapeutics and Immunovant pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities